Member Info for Fundfemale

I just noticed legal and general... It's end of FY and and I am clearly looking at too many figures

That is an impressive holding of SWG - I am only holding 50k. Do you have any angles on this other than it is really undervalued and the financials look good?

Cash is always best ,and for good or for bad, I feel that this is a market for short term investments.I love the look of your CRYO recommendation but as it cannot be held in SIPP or ISA I have to set-up another account asap, so lets follow that one in due course. Yesterday I bought into BII -for the long term and it has announced its first dividend in May. GKP is my first and only oil stock and I am watching it like a hawk, the only good thing is that I spotted the huge directors buys early on, so I am blocking my ears to the hype as I am risk adverse, but I am not loosing sleep over it. I am in Sepura and there is definately some stakebuilding there. I think your strategy is good and like you I am led by my reserch.As i am in the industry and still watching HRG (although currently out), I will let you know if i have any info. If they cut a lot of overhead and were able to focus on higher value bookings they could be more profitable and shift the debt sooner- longer term they are good if they do the right things.

Good news - hope all is well with you. I am currently riding GKP- but cannot wait to get another one off my back.

See the note on Morse below (bottom)- did I get out to early? Morse did nothing for me. I am in GKN though Kurdish lift for Gulf Keystone By Neil Hume and Bryce Elder Published: March 26 2009 02:00 | Last updated: March 26 2009 02:00 Gulf Keystone was in demand yesterday, rising 37 per cent to 8.72p following news of what could be a big oil discovery in the Kurdish region of Iraq. Heritage Oil & Gas, a FTSE 250 company, said it was preparing to test its Miran West-1 exploration well after striking oil. Analysts believe Miran could be a multi-billionbarrel prospect. Morse , the technology consultancy, rose 4.4 per cent to 12p amid talk that the company had rebuffed a 15p-a-share bid approach and was holding out for 20p

Just sold all my MOR (bored and financial software not really attractive at the moment). Increased my SEPU today (lot of trading/possible stakebuilding there) and upped GKP (just before everyone else noticed the Kurdistan news - see heritage). Will look at EML and OVG.

I have been looking at these for weeks and as I would love every share in my portfolio to carry a dividend, I happily gave in and bought. I May buy more if SP drops before ex-dividend date of 29 April 2009. 24 March 2009 BIOCOMPATIBLES INTERNATIONAL PLC ('Biocompatibles' or the 'Company') Dividend Biocompatibles International plc announces that its board of directors has today resolved to pay an interim dividend of 5 pence per ordinary share of 2153 /94 pence each in the share capital of the Company. The dividend, which is based on the royalty income from Abbott Laboratories on sales of Medtronic's Endeavour® Drug-Eluting Stent, is to be paid on 22 May 2009 to the holders of ordinary shares on the register at the close of business on 1 May 2009. The ex-dividend date is 29 April 2009. Ends I have been looking at these for weeks and as I would love every share in my portfolio to carry a dividend, I gave and bought. May buy more if SP drops before ex-dividend date of 29 April 2009.

I think 15.75 too high to top up and agree with Oil Barron that the results may cause a sell-off.

I am watching and would reconsider at the right level, but would like to see year end figures.

I do service UK corporate and other large clients (plus a small percentage of overseas clients) with a global offering.

Looks really good- growth market, directors buys, newly advised dividend, global leader aspirations, NPD., cash. N.B. tried to buy, but could not be bought into SIPP or ISA (euro). Plan to buy- may wait for cool-down after superb results today.

Wow, looks like some good buys there today. I will research it. br

We should have dialogue later

Maybe we do? Where are your contacts?

I have a specialist business operating in part of HRG's market, with a different business model and revenue stream. And you?

Your note re. ebitda is a fair one. As a general note a non-listed company would be likely to pay a higher proportion of profit as dividend as they would be payable to directors vs. general shareholders. This particular area of the market would have a lot of cost synergies in consolidation- no business in this sector would entertain/endure extra overhead at present (or an expensive aquisition).

To Iqu10 - Thanks for message, we can easily become entrenched in our own beliefs and this is why discussion is so useful. I am out of HRG for now, but maybe not for ever if another opportunity comes and I like the outlook. Chique, the new glasses look great on me x Do either of you have any further recommendations to research. I wish you both well with HRG moves.

2009 profits are an estimation at this stage but many companies/agencies in this business have experienced downturn and suffered clients budget cancellations and reductions in this Q. Unless I am on the board or worked in HRG management accounts I can only factor in trends until the results are announced in the next few months. Business valuation is subject to many factors, but I have a business myself in this industry. I fully agree that personal research and conviction is the best thing.

A private company in this business would sell at around 5-7 x net (LY HRG presented approx 17 million before dividend and 6 miliion after dividend). As the dividend would have been covered by the debt anyway, if we take the 6 million net x 7 times (high end of the valuation multiple I mentioned), this would indicate a company valued at 42 million (without factoring in any deterioration in this years results). As the market capitalisation is currently around 49 million plus a debt of 100 million the sp is currently supporting an overvaluation of 107 million. If the share price reduced to 3.5 again, it would have a market value of 10.77 million plus 100 million debt (still, in my opinion 68 million over market value). I am not being negative, but pragmatic, as I feel that many are looking at this share with rose coloured glasses. I feel that I judged an exit at just short of 18p well and I question the judgement of anyone stakebuilding at that level. Of course I have not factored in future increase in sales or profit growth and the value of synergies for any purchaser.

Oppenheimer buy GKP RNS - sorry, tease unintentional!